.svg)
BLOG
The Latest on Solid IO
Solid IO welcomes new international investors
Leo Capital and Life Science Invest have joined Solid IO to support the company's next phase of growth in personalized immuno-oncology.
Solid IO welcomes new international investors
Leo Capital and Life Science Invest have joined Solid IO to support the company's next phase of growth in personalized immuno-oncology.
CSO Heidi Haikala receives the Anders Jahre Prize for Young Scientists
The award recognizes her work on understanding why cancer therapies stop working, with the goal of preventing treatment resistance and identifying new therapeutic targets.
Dr. Peter Loskill joins Solid IO as Scientific Advisor
The pioneer in organ-on-chip systems supports Solid IO in bringing human biology into clinical use.
Human-Based Models Accelerating Immuno-Oncology Drug Development
As pressure grows to generate stronger preclinical evidence earlier in development, biotech companies are increasingly exploring human-based models to improve translational relevance and reduce clinical risk in immuno-oncology programs.
Biotech Founder of the Year award for CSO Heidi Haikala
The award was announced at the Biotech Stars Awards by Finnish Bioindustries FIB.
Solid IO on stage at the European DeepTech Week
Solid IO representing the most promising European deep tech startups in life science at European DeepTech Week in Paris in March 2026.
Shape the future of cancer care
Join SolidIO in transforming cancer care with groundbreaking organ-on-chip technology. We’re calling on researchers, clinicians, and investors to partner with us in advancing precision medicine, accelerating innovation, and expanding global access to personalized oncology. Together, we can bring clarity and better outcomes to cancer care worldwide.